Huons Co., Ltd. (243070.KQ)
KRW 28400.0
(1.79%)
KRW 28400.0
(1.79%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 74.23 Billion KRW | 30.59% |
| 2022 | 57.59 Billion KRW | -1.9% |
| 2021 | 58.12 Billion KRW | -13.15% |
| 2020 | 65.95 Billion KRW | 13.22% |
| 2019 | 58.25 Billion KRW | 12.66% |
| 2018 | 51.7 Billion KRW | 24.68% |
| 2017 | 41.47 Billion KRW | 61.3% |
| 2016 | 25.12 Billion KRW | 0.0% |
| 2014 | 31.33 Billion KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 15.91 Billion KRW | -6.25% |
| 2024 Q2 | 14.39 Billion KRW | -9.74% |
| 2023 Q2 | 22.11 Billion KRW | 42.94% |
| 2023 FY | - KRW | 30.59% |
| 2023 Q4 | 16.51 Billion KRW | -14.35% |
| 2023 Q1 | 15.47 Billion KRW | -22.02% |
| 2023 Q3 | 19.28 Billion KRW | -12.82% |
| 2022 Q2 | 14.32 Billion KRW | -6.64% |
| 2022 Q4 | 19.84 Billion KRW | 177.14% |
| 2022 Q3 | 7.16 Billion KRW | -50.03% |
| 2022 Q1 | 15.34 Billion KRW | 111.7% |
| 2022 FY | - KRW | -1.9% |
| 2021 Q2 | 15.66 Billion KRW | -6.27% |
| 2021 FY | - KRW | -13.15% |
| 2021 Q1 | 16.7 Billion KRW | -2.93% |
| 2021 Q4 | 7.24 Billion KRW | -59.06% |
| 2021 Q3 | 17.7 Billion KRW | 13.06% |
| 2020 Q3 | 18.33 Billion KRW | 13.29% |
| 2020 Q1 | 14.21 Billion KRW | -13.4% |
| 2020 Q2 | 16.18 Billion KRW | 13.88% |
| 2020 FY | - KRW | 13.22% |
| 2020 Q4 | 17.21 Billion KRW | -6.14% |
| 2019 Q2 | 10.9 Billion KRW | -22.73% |
| 2019 FY | - KRW | 12.66% |
| 2019 Q4 | 16.41 Billion KRW | -2.33% |
| 2019 Q3 | 16.8 Billion KRW | 54.18% |
| 2019 Q1 | 14.1 Billion KRW | 43.91% |
| 2018 FY | - KRW | 24.68% |
| 2018 Q2 | 13.32 Billion KRW | 0.67% |
| 2018 Q3 | 15.33 Billion KRW | 15.07% |
| 2018 Q1 | 13.23 Billion KRW | 20.86% |
| 2018 Q4 | 9.8 Billion KRW | -36.09% |
| 2017 Q1 | 8.74 Billion KRW | -59.46% |
| 2017 FY | - KRW | 61.3% |
| 2017 Q4 | 10.95 Billion KRW | -18.49% |
| 2017 Q3 | 13.43 Billion KRW | 28.22% |
| 2017 Q2 | 10.48 Billion KRW | 19.86% |
| 2016 Q3 | 11.06 Billion KRW | 0.0% |
| 2016 FY | - KRW | 0.0% |
| 2016 Q4 | 21.57 Billion KRW | 94.97% |
| 2014 FY | - KRW | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| HLB Pharmaceutical Co., Ltd | 581.09 Million KRW | -12674.727% |
| CMG Pharmaceutical Co., Ltd. | 5.59 Billion KRW | -1226.886% |
| Celltrion Pharm, Inc. | 54.22 Billion KRW | -36.9% |
| Huons Global Co., Ltd. | 151.92 Billion KRW | 51.14% |
| DongKook Pharmaceutical Co., Ltd. | 88.68 Billion KRW | 16.297% |
| Enzychem Lifesciences Corporation | -5.77 Billion KRW | 1385.704% |
| Humedix Co., Ltd. | 54.87 Billion KRW | -35.277% |
| Boditech Med Inc. | 36.48 Billion KRW | -103.441% |
| EuBiologics Co., Ltd. | -4.39 Billion KRW | 1790.249% |
| FutureChem Co.,Ltd | -591.25 Million KRW | 12655.08% |
| BNC Korea Co., Ltd. | 14.17 Billion KRW | -423.817% |
| AptaBio Therapeutics Inc. | -13 Billion KRW | 670.819% |